Moving toward personalized medicine in castration-resistant prostate cancer.
Recent advances in research technologies have allowed improved molecular characterization of castration-resistant prostate cancer (CRPC). These efforts hold promise for development of therapies that target alterations unique to an individual patient's prostate cancer. Targets include androgens and the androgen receptor pathway, pathways associated with hormone-resistant disease, and the immune system. In aggregate, this will allow physicians to choose treatments based on a particular tumor profile. As these approaches are developed, CRPC treatment is becoming an example of truly personalized medicine.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Eliezer M
EM
Van Allen
Mark
M
Pomerantz
D000728:Androgens / Q000502:physiology; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002352:Carrier Proteins / Q000502:physiology; D018450:Disease Progression; D006801:Humans; D007167:Immunotherapy; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000628:therapy*; D057285:Precision Medicine; D011471:Prostatic Neoplasms / Q000503:physiopathology / Q000556:secondary / Q000628:therapy*; D011944:Receptors, Androgen / Q000187:drug effects* / Q000502:physiology; D014359:Trypsin Inhibitor, Kazal Pancreatic
D000728:Androgens; D000970:Antineoplastic Agents; D002352:Carrier Proteins; D011944:Receptors, Androgen; C486642:SPINK1 protein, human; D014359:Trypsin Inhibitor, Kazal Pancreatic